Navigation Links
EntreMed Reports Fourth Quarter And Year-End 2012 Financial Results And Business Outlook For 2013
Date:3/21/2013

xpectations. Our research and development expenses for the fourth quarter increased compared to the previous year as we began operations in China in 2012 and also initiated a dual-institutional Phase 2 study of ENMD-2076 in triple-negative breast cancer.  We anticipate operating expenses to increase in 2013 as we execute on our clinical development plan in the US and China.  Royalty revenues from Celgene's sales of Thalomid® in 2012 were $0.7 million, compared to $1.9 million in 2011.  The decrease in royalty revenues was in line with our expectations and results from a decline in sales of Thalomid® in the United States."  Further up-to-date information regarding the Company, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2012, can be found on our web site at www.entremed.com.

Dr. Ken Ren , Chief Executive Officer, commented, "We are pleased with our financial results for the year and quarter ended December 31, 2012, which reflect our success in reducing operating costs and at the same time reflect new costs for implementing new programs, including initiating our Phase 2 triple-negative breast trial at two US sites, establishing our office in Beijing, initiating local manufacturing activities in China, and the filing of a new clinical trial application with the Chinese SFDA.  Since the year ended, we also initiated a Phase 2 clinical trial in advanced metastatic soft tissue sarcoma at Princess Margaret Hospital in Canada.  We are pleased with our recent financing and the support and encouragement from new institutional shareholders from both the US and China.  We intend to use the proceeds to further the global clinical development of ENMD-2076 and for general business development and corpo
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. EntreMed Reports First Quarter 2012 Financial Results
2. EntreMed Announces Initiation Of Phase 2 Trial In Triple-negative Breast Cancer
3. EntreMed Reports Second Quarter 2012 Financial Results
4. Dana-Farber Cancer Institutes Ursula A. Matulonis, MD Article on EntreMeds ENMD-2076 Published in the European Journal of Cancer
5. EntreMed Announces Publication Of Preclinical Results For ENMD-2076 In Triple-negative Breast Cancer
6. PNAS Publishes Preclinical Results of EntreMeds 2ME2 for Multiple Sclerosis
7. EntreMed Announces Initiation Of Phase 2 Trial In Advanced/Metastatic Soft Tissue Sarcoma
8. EntreMed To Raise $10.7 Million In Registered Direct Offering
9. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
10. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
11. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 Neurelis, Inc. ("Neurelis") today ... end the option held by Biotie to purchase Neurelis, ... of NRL-1 (intranasal diazepam) for pediatric and adult epilepsy ... the past year, Biotie has advanced the development program ... the pivotal clinical work required for NDA submission to ...
(Date:7/10/2014)... , July 10, 2014  Breg, Inc., a ... has launched the FreeRunner™ knee brace with new ... from patella mal-tracking return to active lifestyles.  FreeRunner,s ... other braces, providing support when patients need it ... they don,t. Patellofemoral issues are the ...
(Date:7/10/2014)... WEST JORDAN, Utah , July 10, 2014 /PRNewswire/ ... imaging solutions, and MiE America , Inc., a ... systems, have entered into a long-term agreement naming BC ... in the US. MiE and BC ... a strategic agreement to establish BC Technical as the ...
Breaking Medicine Technology:Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2
... and IRVINE, Calif., May 6, 2011 CryoLife, Inc. ... device and cardiovascular tissue processing company, today announced the ... through its wholly owned subsidiary CL Falcon, Inc., for ... ("Cardiogenesis") (OTCQB: CGCP).  The tender offer expired at 12:00 ...
... The Female Health Company (NASDAQ-CM: FHCO) today announced ... Comercio (Semina), was successful in a public tender to ... to 20 million FC2 Female Condoms.  The contract is ... will be determined at the Ministry of Health,s discretion. ...
Cached Medicine Technology:CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation 2CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation 3CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation 4CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation 5CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation 6The Female Health Company's Brazilian Distributor, Semina, Awarded Contract For Up To 20 Million FC2 Female Condoms 2The Female Health Company's Brazilian Distributor, Semina, Awarded Contract For Up To 20 Million FC2 Female Condoms 3
(Date:7/11/2014)... 11, 2014 Ticket Down reports that tickets ... and 3rd place World Cup Match between Brazil and ... will take place on Saturday, July 12th at Estadio Nacional ... Finals will take place on Sunday, July 13th at Estadio ... All tickets for the 2014 World Cup are guaranteed to ...
(Date:7/11/2014)... July 11, 2014 (HealthDay News) -- Reducing the number ... incidence of Lyme disease and other tick-borne infections among ... deer populations can be manipulated to reduce human interactions ... contracting Lyme disease," the researchers wrote. White-tailed deer ... transmit Lyme disease to people. The study included ...
(Date:7/11/2014)... 11, 2014 Volunteers from Scientology ... abuse this week with drug education lectures, forums and ... distribution in cities around the world. , Drug abuse ... Institute on Drug Abuse, abuse of alcohol and illicit ... crime, lost work, decreased productivity and healthcare. , ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 The ... by Types, Applications & Geography - 2018,” defines ... fiber market with an analysis and forecast of ... specialty synthetic fibers (Para aramids, meta aramids, UHMW ... others including PPS fiber, PBI fiber, PBO fiber, ...
(Date:7/11/2014)... 11, 2014 Utilizing the Keller Funnel, ... William Koenig, has topped a record number of complication-free ... performed over 400 successful procedures without the occurrence of ... well known across the country for his expertise with ... has long been the foundation for numerous studies and ...
Breaking Medicine News(10 mins):Health News:Argentina vs. Germany World Cup Finals Tickets & Brazil vs. Netherlands 3rd Place World Cup Tickets Are in Huge Demand 2Health News:Scientologists Taking Action against Drug Abuse 2Health News:Scientologists Taking Action against Drug Abuse 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 2Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 4Health News:Rochester Surgeon Hits Milestone with Keller Funnel 2
... ... ... ... ...
... , ... ... ... ...
... ... ... , ... , , ...
... ... ... , , ... WASHINGTON , ...
... type of blood cancer, mixed lineage leukemia (MLL), has an ... cells rely on the normal version of an associated protein ... of chromosome 11 breaks off at the normal MLL-associated gene. ... a fusion protein that eventually causes uncontrolled growth of blood ...
... ... Health Systems. The Meaningful Use Dashboard will provide a single location where an organization ... Indicators. , ... OH (PRWEB) February 26, 2010 -- Health Care DataWorks , a Technology Company ...
Cached Medicine News:Health News:Prominent New York City Real Estate Investor, Attorney and Atlanta Nursing Home Chains Pay $14 Million to Settle Whistleblower Kickback Case 2Health News:Prominent New York City Real Estate Investor, Attorney and Atlanta Nursing Home Chains Pay $14 Million to Settle Whistleblower Kickback Case 3Health News:Prominent New York City Real Estate Investor, Attorney and Atlanta Nursing Home Chains Pay $14 Million to Settle Whistleblower Kickback Case 4Health News:Prominent New York City Real Estate Investor, Attorney and Atlanta Nursing Home Chains Pay $14 Million to Settle Whistleblower Kickback Case 5Health News:Prominent New York City Real Estate Investor, Attorney and Atlanta Nursing Home Chains Pay $14 Million to Settle Whistleblower Kickback Case 6Health News:Prominent New York City Real Estate Investor, Attorney and Atlanta Nursing Home Chains Pay $14 Million to Settle Whistleblower Kickback Case 7Health News:Prominent New York City Real Estate Investor, Attorney and Atlanta Nursing Home Chains Pay $14 Million to Settle Whistleblower Kickback Case 8Health News:CPR Instruction Via Cell Phone Effective 2Health News:CPR Instruction Via Cell Phone Effective 3Health News:CPR Instruction Via Cell Phone Effective 4Health News:Fifth Anniversary of Global Tobacco Control Treaty Presents Opportunity For U.S. Ratification and Leadership 2Health News:Fifth Anniversary of Global Tobacco Control Treaty Presents Opportunity For U.S. Ratification and Leadership 3Health News:Fifth Anniversary of Global Tobacco Control Treaty Presents Opportunity For U.S. Ratification and Leadership 4Health News:Two Atlanta-Based Nursing Home Chains and Their Principals Pay $14 Million to Settle False Claims Act Case 2Health News:Two Atlanta-Based Nursing Home Chains and Their Principals Pay $14 Million to Settle False Claims Act Case 3Health News:Two Atlanta-Based Nursing Home Chains and Their Principals Pay $14 Million to Settle False Claims Act Case 4Health News:Two Atlanta-Based Nursing Home Chains and Their Principals Pay $14 Million to Settle False Claims Act Case 5Health News:Cells of aggressive leukemia hijack normal protein to grow 2Health News:HCD Announces Meaningful Use Dashboard for Health Systems 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: